Our role as a genomics pioneer brings with it the responsibility to enable innovation for good, ensuring that the technology we create and the data we collect are used safely, ethically, and responsibly.
Videos from Client
Responsible Business & Employee Engagement
| Illumina
Illumina has always been committed to a more equitable and sustainable future, and the challenges of 2020 gave us myriad opportunities to demonstrate our shared values and global citizenship.
We entered 2021 full of hope for a recovery from the pandemic, at the dawn of a new era of genomic medicine, and a recognition of the incredible opportunities for us to rebuild a healthier, more inclusive, and more sustainable global community.
Illumina has been included for the first time on the 2022 100 Best Corporate Citizens list by 3BL Media, recognizing outstanding environmental, social, and governance (ESG) performance among the 1,000 largest U.S. public companies.
Two years into the pandemic that has killed millions and shaken the global economy, the world still lacks a unified effort to detect and fight future outbreaks using genetic tools, said Illumina Inc. Chief Executive Officer Francis deSouza.
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today released its annual Corporate Social Responsibility (CSR) Report, highlighting the company's 2021 environmental, social, and governance (ESG) program and commitment to human health.
We are honored to be recognized as #32 by CNBC and JUST Capital in the Americas Most JUST rankings and #1 for customers in the Pharmaceuticals and Biotech industry.
We are delighted that Illumina is the top ranked Healthcare and Life Science company and #2 overall on Newsweek’s America’s Most Responsible Companies 2022 list, which recognizes top-performing companies that are making a difference through their environmental, social and governance actions.
Each year, Fortune Magazine publishes their ChangeTheWorld list to celebrate companies and leaders that embrace corporate purpose and have had a positive social impact
“We need global co-operation to come together on a number of fronts,” says deSouza. The first challenge, he says, is creating a global network that scans and shares information on disease-causing pathogens.
Our role as a genomics pioneer brings with it the responsibility to enable innovation for good, ensuring that the technology we create and the data we...